Wells Fargo’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.39M | Sell |
1,004,041
-243
| -0% | -$669 | ﹤0.01% | 3440 |
|
|
2026
Q1 | $2.76M | Sell |
1,004,284
-2,005
| -0.2% | -$6.23K | ﹤0.01% | 3022 |
|
|
2025
Q4 | $3.16M | Sell |
1,006,289
-4,232
| -0.4% | -$13.3K | ﹤0.01% | 3073 |
|
|
2025
Q3 | $2.92M | Sell |
1,010,521
-14,087
| -1% | -$31.8K | ﹤0.01% | 3034 |
|
|
2025
Q2 | $2.08M | Buy |
1,024,608
+26,987
| +3% | +$46.9K | ﹤0.01% | 3192 |
|
|
2025
Q1 | $1.87M | Buy |
997,621
+1,985
| +0.2% | +$5K | ﹤0.01% | 3213 |
|
|
2024
Q4 | $2.69M | Sell |
995,636
-112,402
| -10% | -$351K | ﹤0.01% | 2961 |
|
|
2024
Q3 | $4.19M | Sell |
1,108,038
-13,979
| -1% | -$48.8K | ﹤0.01% | 2485 |
|
|
2024
Q2 | $4.48M | Buy |
1,122,017
+2,314
| +0.2% | +$7.66K | ﹤0.01% | 2348 |
|
|
2024
Q1 | $3.31M | Sell |
1,119,703
-28,988
| -3% | -$104K | ﹤0.01% | 2576 |
|
|
2023
Q4 | $5.74M | Buy |
1,148,691
+2,605
| +0.2% | +$8.37K | ﹤0.01% | 2117 |
|
|
2023
Q3 | $3.27M | Buy |
1,146,086
+6,328
| +0.6% | +$19.3K | ﹤0.01% | 2426 |
|
|
2023
Q2 | $3.37M | Buy |
1,139,758
+162,926
| +17% | +$356K | ﹤0.01% | 2476 |
|
|
2023
Q1 | $2.29M | Buy |
976,832
+246,908
| +34% | +$572K | ﹤0.01% | 2756 |
|
|
2022
Q4 | $1.49M | Buy |
729,924
+78,366
| +12% | +$202K | ﹤0.01% | 2983 |
|
|
2022
Q3 | $2.06M | Buy |
651,558
+109,794
| +20% | +$346K | ﹤0.01% | 2717 |
|
|
2022
Q2 | $1.96M | Buy |
541,764
+50,408
| +10% | +$172K | ﹤0.01% | 2815 |
|
|
2022
Q1 | $1.97M | Buy |
491,356
+77,276
| +19% | +$335K | ﹤0.01% | 3319 |
|
|
2021
Q4 | $2.05M | Buy |
414,080
+61,780
| +18% | +$359K | ﹤0.01% | 3471 |
|
|
2021
Q3 | $2.36M | Buy |
352,300
+17,196
| +5% | +$123K | ﹤0.01% | 3515 |
|
|
2021
Q2 | $2.66M | Buy |
335,104
+14,175
| +4% | +$98K | ﹤0.01% | 3433 |
|
|
2021
Q1 | $2.44M | Sell |
320,929
-2,525
| -0.8% | -$18K | ﹤0.01% | 3513 |
|
|
2020
Q4 | $1.67M | Buy |
323,454
+115,509
| +56% | +$589K | ﹤0.01% | 3623 |
|
|
2020
Q3 | $1.01M | Buy |
207,945
+27,803
| +15% | +$200K | ﹤0.01% | 3854 |
|
|
2020
Q2 | $1.21M | Sell |
180,142
-29,398
| -14% | -$214K | ﹤0.01% | 3657 |
|
|
2020
Q1 | $1.45M | Buy |
209,540
+2,526
| +1% | +$19.7K | ﹤0.01% | 3272 |
|
|
2019
Q4 | $1.76M | Buy |
207,014
+100
| +0% | +$666 | ﹤0.01% | 3443 |
|
|
2019
Q3 | $1.02M | Buy |
206,914
+87,220
| +73% | +$467K | ﹤0.01% | 3825 |
|
|
2019
Q2 | $664K | Hold |
119,694
| – | – | ﹤0.01% | 4179 |
|
|
2019
Q1 | $604K | Buy |
+119,694
| New | +$761K | ﹤0.01% | 4216 |
|
|
2018
Q1 | – | Sell |
-9,948
| Closed | -$127K | – | 6335 |
|
|
2017
Q4 | $127K | Sell |
9,948
-18
| -0.2% | -$212 | ﹤0.01% | 5197 |
|
|
2017
Q3 | $111K | Buy |
+9,966
| New | +$85.3K | ﹤0.01% | 5189 |
|
|
2017
Q2 | – | Sell |
-250
| Closed | -$3K | – | 6184 |
|
|
2017
Q1 | $3K | Hold |
250
| – | – | ﹤0.01% | 6102 |
|
|
2016
Q4 | $3K | Buy |
+250
| New | +$3.46K | ﹤0.01% | 6026 |
|
Other funds holding ACIU
Wells Fargo's ACIU Position: Q2 2026 in Review
Wells Fargo reduced its AC Immune (ACIU) stake by 0.02% in Q2 2026, selling an estimated $669 and leaving 1,004,041 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3440.
Wells Fargo first reported a position in ACIU in Q4 2016 and has held it in 34 quarters since. The position peaked at $5.74M in Q4 2023. 37 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Wells Fargo held 1,004,041 shares of AC Immune worth $2.39M as of Q2 2026.
- Wells Fargo sold 243 AC Immune shares in Q2 2026, an estimated $669.
- AC Immune made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3440 holding.
- Wells Fargo first reported a position in AC Immune in Q4 2016 and has held it in 34 quarters since.
- Wells Fargo's AC Immune position peaked at $5.74M in Q4 2023.
- 37 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.